 Arbutus Biopharma Corporation NASDAQ: ABUS has announced preliminary data from its Phase 1a1b trial of AB-836, an oral hepatitis B virus HBV capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. Arbutus shares are soaring after the Patent Trial and Appeals Board has turned down Moderna Incs NASDAQ: MRNA appeal to invalidate two of Arbutus patents on the COVID-19 Vaccine Delivery Technology Patent. 